Tocagen Inc. (TOCA)’s Financial Results Comparing With Prana Biotechnology Limited (NASDAQ:PRAN)

Tocagen Inc. (NASDAQ:TOCA) and Prana Biotechnology Limited (NASDAQ:PRAN) compete against each other in the Biotechnology sector. We will compare them and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tocagen Inc. 18.04M 13.86 40.19M -2.02 0.00
Prana Biotechnology Limited N/A 0.00 N/A -0.67 0.00

In table 1 we can see Tocagen Inc. and Prana Biotechnology Limited’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows Tocagen Inc. and Prana Biotechnology Limited’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Tocagen Inc. -222.78% -71.6% -46.1%
Prana Biotechnology Limited 0.00% -37.8% -34.3%


The Current Ratio of Tocagen Inc. is 5.8 while its Quick Ratio stands at 5.8. The Current Ratio of rival Prana Biotechnology Limited is 7.1 and its Quick Ratio is has 7.1. Prana Biotechnology Limited is better equipped to clear short and long-term obligations than Tocagen Inc.

Institutional & Insider Ownership

Institutional investors owned 31% of Tocagen Inc. shares and 3.5% of Prana Biotechnology Limited shares. Tocagen Inc.’s share owned by insiders are 7.6%. Insiders Comparatively, owned 18.7% of Prana Biotechnology Limited shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Tocagen Inc. -1.47% 5.39% 3.76% 31.85% 19.68% 24%
Prana Biotechnology Limited -9.31% -14.69% -22.56% -22.61% -50.97% -51.6%

For the past year Tocagen Inc. has 24% stronger performance while Prana Biotechnology Limited has -51.6% weaker performance.


On 6 of the 9 factors Prana Biotechnology Limited beats Tocagen Inc.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The companyÂ’s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG). It is also developing Toca 511 & Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.

Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of AlzheimerÂ’s: and that is in Phase IIa clinical trials for the treatment of HuntingtonÂ’s diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for ParkinsonÂ’s disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.